NERVIGESIC D CAP is a highly effective and scientifically formulated combination of Pregabalin and Duloxetine, designed to address the complex symptoms of neuropathic pain and associated mood disorders. It is particularly beneficial for patients suffering from chronic nerve pain due to conditions like diabetic neuropathy, postherpetic neuralgia, fibromyalgia, spinal cord injury, and generalized anxiety disorder.
Pregabalin, a structural analog of gamma-aminobutyric acid (GABA), works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This action reduces the release of excitatory neurotransmitters such as glutamate, noradrenaline, and substance P, which are involved in the transmission of pain. As a result, Pregabalin exerts an analgesic and anticonvulsant effect, significantly reducing the severity of nerve pain and enhancing sleep quality.
Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), complements the action of Pregabalin by modulating the levels of key neurotransmitters—serotonin and norepinephrine—in the brain. This mechanism not only helps in alleviating depression and anxiety that frequently accompany chronic pain but also contributes directly to pain inhibition by enhancing descending inhibitory pain pathways.
The combination of Pregabalin and Duloxetine in NERVIGESIC D CAP provides a dual mechanism of action, making it superior to monotherapy in both efficacy and patient outcomes. Patients often report a significant reduction in pain intensity, improved sleep patterns, better emotional well-being, and enhanced daily functioning.
NERVIGESIC D CAP is manufactured by Bluepill Express in state-of-the-art WHO-GMP certified facilities, ensuring consistent quality, safety, and regulatory compliance. The formulation is encapsulated in moisture-resistant hard gelatin capsules, providing excellent bioavailability and patient compliance. The dosing is tailored for once or twice-daily administration depending on clinical need, under the supervision of a qualified healthcare professional.
This product is particularly suitable for inclusion in chronic care regimens, especially for those experiencing overlapping symptoms of neuropathic pain and depressive or anxiety disorders. By addressing both the physical and emotional aspects of nerve pain, NERVIGESIC D CAP serves as a comprehensive treatment option in neurology and psychiatry.
The formulation is generally well-tolerated. However, mild side effects such as dizziness, somnolence, dry mouth, constipation, or mild weight gain may occur in some patients. Clinical judgment is advised before prescribing to individuals with hepatic impairment, renal dysfunction, or a history of substance abuse.
In global pharmaceutical markets, NERVIGESIC D CAP stands out as a trusted and effective solution for neuropathic conditions and mood disturbances. Bluepill Express also offers third-party manufacturing services for this formulation, with custom branding, packaging, and export capabilities across regulated and semi-regulated markets.
Description provided by bluepill express.
FIEO Registered
Export Ready
